Investigating polypharmacy and drug burden index in hospitalised older peopleGiles Best, Andrew J. McLachlan, Danijela Gnjidic et al.|Internal Medicine Journal|2013Cited by 117
A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and ToxicityStephen P. Mulligan, Bryone J. Kuss, Devinder Gill et al.|Blood|2014Cited by 21
A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 StudyStephen P. Mulligan, Bryone J. Kuss, Rosemary Harrup et al.|Blood|2012Cited by 14
Chronic lymphocytic leukaemia Australasian consensus practice statementMary Ann Anderson, Stephen P. Mulligan, Rory Bennett et al.|Internal Medicine Journal|2023Cited by 12
Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)Stephen P. Mulligan, Bryone J. Kuss, Devinder Gill et al.|Blood|2014Cited by 5